HS
HighVista Strategies Portfolio holdings
AUM
$272M
1-Year Return
24.34%
This Quarter Return
-4.54%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$260M
AUM Growth
-$9.28M
(-3.5%)
Cap. Flow
+$7.65M
Cap. Flow
% of AUM
2.95%
Top 10 Holdings %
Top 10 Hldgs %
25.84%
Holding
172
New
35
Increased
39
Reduced
27
Closed
24
Top Buys
| 1 |
Quanta Services
PWR
|
$2.06M |
| 2 |
Bausch Health
BHC
|
$2.03M |
| 3 |
Mastercard
MA
|
$2.03M |
| 4 |
3M
MMM
|
$1.98M |
| 5 |
MasTec
MTZ
|
$1.9M |
Top Sells
| 1 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
$4.45M |
| 2 |
Amazon
AMZN
|
$2.95M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$2.23M |
| 4 |
Live Nation Entertainment
LYV
|
$2.02M |
| 5 |
Indivior
INDV
|
$1.83M |
Sector Composition
| 1 | Healthcare | 39.15% |
| 2 | Technology | 17.75% |
| 3 | Industrials | 8.61% |
| 4 | Consumer Discretionary | 6.17% |
| 5 | Financials | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Keros Therapeutics
KROS
$636M
| $531K | 0.2% |
52,107
| – | – |
|
127
Zymeworks
ZYME
$1.08B
| $496K | 0.19% |
+41,607
| New | +$496K |
|
128
Ultragenyx Pharmaceutical
RARE
$3.07B
| $483K | 0.19% |
+13,328
| New | +$483K |
|
129
JD.com
JD
$44.2B
| $460K | 0.18% |
11,183
+400
| +4% | +$16.4K |
|
130
Wave Life Sciences
WVE
$1.35B
| $431K | 0.17% |
+53,374
| New | +$431K |
|
131
Mirum Pharmaceuticals
MIRM
$3.79B
| $403K | 0.16% |
8,942
| – | – |
|
132
Corbus Pharmaceuticals
CRBP
$123M
| $400K | 0.15% |
75,292
| – | – |
|
133
KalVista Pharmaceuticals
KALV
$778M
| $384K | 0.15% |
33,305
| – | – |
|
134
Pharvaris
PHVS
$1.43B
| $357K | 0.14% |
22,768
| – | – |
|
135
Xencor
XNCR
$616M
| $340K | 0.13% |
31,942
| – | – |
|
136
Sarepta Therapeutics
SRPT
$1.96B
| $333K | 0.13% |
+5,212
| New | +$333K |
|
137
Disc Medicine
IRON
$2.12B
| $321K | 0.12% |
6,458
| – | – |
|
|
ABVX
138
Abivax
ABVX
$6.38B
| $307K | 0.12% |
49,064
| – | – |
|
139
Structure Therapeutics
GPCR
$1.16B
| $304K | 0.12% |
17,561
| – | – |
|
140
Perspective Therapeutics
CATX
$278M
| $295K | 0.11% |
138,350
| – | – |
|
141
Arvinas
ARVN
$576M
| $290K | 0.11% |
41,271
-16,730
| -29% | -$117K |
|
142
Cullinan Oncology
CGEM
$409M
| $241K | 0.09% |
31,893
| – | – |
|
143
Kymera Therapeutics
KYMR
$3.12B
| $239K | 0.09% |
8,733
| – | – |
|
144
Kanzhun
BZ
$11B
| $228K | 0.09% |
+11,900
| New | +$228K |
|
145
Tyra Biosciences
TYRA
$668M
| $223K | 0.09% |
23,941
| – | – |
|
146
Geron
GERN
$874M
| $202K | 0.08% |
127,284
| – | – |
|
147
Erasca
ERAS
$437M
| $186K | 0.07% |
135,667
| – | – |
|
148
Pliant Therapeutics
PLRX
$106M
| $148K | 0.06% |
+109,938
| New | +$148K |
|
149
Adobe
ADBE
$148B
| – | – |
-2,700
| Closed | -$1.2M |
|
|
AUTL
150
Autolus Therapeutics
AUTL
$378M
| – | – |
-533,024
| Closed | -$1.25M |
|